Serrix
Serrix BV is an Amsterdam-based consumer health company that develops and distributes OTC healthcare products through three proprietary brands—Mycosan (antifungal), SoreFix (cold sore), and donttellmum (paediatric skincare)—sold across 25+ countries via a pharmaceutical distributor network.
- Company typePrivate
- Founded2007
- HeadquartersAmsterdam, Netherlands
- Headcount11–50
- GTM typeB2C
- OfferingHardware or Manufacturing
What Serrix does
Serrix BV is a Dutch consumer health company founded in 2007 by Ruben Visser and headquartered in Amsterdam. The company develops and commercializes over-the-counter (OTC) healthcare products across three proprietary brands: Mycosan (antifungal foot care treatments featuring brush applicator technology for athlete's foot and fungal nail infections), SoreFix (a cold sore treatment using a proprietary zinc-based oil formula designed to be effective across all four stages from tingling to scab), and donttellmum (a paediatric skincare line for children 0–12 years featuring Eczema Repair with skin lipid technology and 100% vegetable petrolatum). The portfolio targets common, high-frequency consumer health conditions amenable to self-medication, with products clinically validated and registered as medical devices.
The company operates a B2B distributor-led go-to-market model, selling through pharmaceutical distribution partners in over 25 countries. More than two-thirds of sales are generated outside the Netherlands, with primary geographic focus on Central and Eastern Europe and the wider CSI (Commonwealth of Independent States) region. Serrix supports its distributor network with marketing strategy, brand training, and product registration expertise—particularly valuable within the EU—and established its own Dutch distribution center in 2021 to capture logistics margin and improve service levels in its home market. The company is founder-owned and operated, with a small team (~12–13 visible personnel across management, sales, regulatory, R&D, and operations functions), no institutional capital, and no public listing.
Commercially, Serrix monetizes through wholesale product sales to distributors, who in turn supply pharmacies and drugstores reaching thousands of consumers weekly. The company achieved a major regulatory milestone in 2023 with EU MDR (Medical Device Regulation 2017/745) certification across all three brands, securing continued EU market access under tightened regulation. Notable commercial proofs include Mycosan being recognized as the fastest-growing OTC brand in the Netherlands (2010), SoreFix becoming the #1 cold sore product in Dutch pharmacies (2014), and cumulative sales exceeding 10 million units of Mycosan Fungal Nail Treatment by 2015. The company has stated a public ambition to double the size of the business within three years and actively seeks innovation partners for co-development and licensing in adjacent consumer health categories.
Serrix firmographics
Firmographics- Name
- Serrix
- Legal name
- Serrix BV
- Website
- https://serrix.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Serrix BV is an Amsterdam-based consumer health company that develops and distributes OTC healthcare products through three proprietary brands—Mycosan (antifungal), SoreFix (cold sore), and donttellmum (paediatric skincare)—sold across 25+ countries via a pharmaceutical distributor network.
- Ownership category
- akta.pro rank
Serrix industry classification
Industry- Product category
- OTC Consumer Health Products
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Dermatology OTC & Skin Health (Acne Treatments, Eczema/Psoriasis OTC, Antifungals, Wart Removal) (CRADAMAF)
- akta.pro secondary industries
- Foot Care & Orthotics OTC (Corn/Callus Care, Insoles, Athlete’s Foot Treatments) (CRADAMAL), Dermatology & Topical Skin Treatments (HLAIADAE), Dermocosmetics & Medical-Grade Skincare (CRABAAAF), Hand & Foot Care (CRABAAAE)
Keywords
Where Serrix is headquartered
LocationHeadquarters
- HQ city
- Amsterdam
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
Serrix business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Consumer Health Product Sales: Serrix generates revenue through the sale of OTC consumer health products via its worldwide distributor network. Products include anti-fungal treatments (Mycosan), cold sore solutions (SoreFix), and paediatric skincare (donttellmum). Revenue is realized through B2B relationships with distributors across 25+ countries.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Serrix product offering
Product offeringCore offering
Serrix develops and sells OTC (over-the-counter) consumer health products through three proprietary brands: Mycosan (antifungal foot care including fungal nail and athlete's foot treatments), SoreFix (cold sore treatment using a unique zinc formula), and donttellmum (paediatric skincare for babies and kids 0-12 years including eczema repair). Products are sold in over 25 countries worldwide through a distributor network serving consumers via pharmacies and drugstores.
Product overview
Serrix is an entrepreneurial consumer health company that develops and sells OTC (over-the-counter) healthcare products. The company's portfolio consists of three main brands: Mycosan (antifungal foot care products including fungal nail treatment, athlete's foot gel, protect, and foot/shoe powder), SoreFix (cold sore treatment), and donttellmum (paediatric skincare including eczema repair). These brands are sold in over 25 countries and serve thousands of consumers weekly. The products are developed for self-care, focusing on making health accessible and convenient for consumers to feel good, look good, and get more out of life.
Differentiator
Problem solved
Functional benefit
Brands
- Mycosan: Specialist antifungal foot care products line for treatment and prevention of athlete's foot and fungal nail infections. Includes Fungal Nail Treatment, Athlete's Foot Gel, Protect, and Foot & Shoe Powder.
- SoreFix
- donttellmum
Products and services
- Mycosan Fungal Nail Treatment Specialist antifungal treatment for fungal nail infections using unique brush applicator technology for easy and hygienic application, providing fast visible results. Targeted at consumers seeking OTC treatment of fungal nail conditions.
- Mycosan Athlete's Foot Gel Treatment gel for athlete's foot with proven efficacy and convenient application. Targeted at consumers with athlete's foot fungal infections.
- Mycosan Protect Protective product line to prevent fungal reinfection on feet and nails. Targeted at consumers seeking to prevent recurrent fungal infections.
- Mycosan Foot & Shoe Powder Powder product for foot hygiene and prevention of fungal infection in shoes. Targeted at consumers seeking to maintain foot hygiene and prevent reinfection.
- SoreFix - Total Cold Sore Solution Total cold sore solution using a unique zinc formula based on oil, effective in all four stages of cold sore from tingling to scab. Targeted at consumers suffering from cold sores (Herpes Simplex Labialis).
- donttellmum Eczema Repair Clinically proven eczema treatment using unique skin lipid technology containing all 3 skin identical lipids and 100% vegetable petrolatum as a sustainable alternative to petro-chemical variants. Designed for babies and kids 0-12 years with atopic dermatitis/eczema.
- donttellmum Paediatric Skincare Range First line skincare range for the treatment of common kids ailments, developed for babies and kids 0-12 years with proven efficacy, best ingredients, and convenient use. Targeted at parents seeking gentle, effective skincare for young children.
Quantifiable outcome
- 10,000,000+ units sold of Mycosan Fungal Nail Treatment by 2015
- +2 more outcomes
Companies that use Serrix
Customer profileNamed customers4 records
Segments2 records
Ideal customer profiles2 records
Serrix technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Serrix partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- AswatsoncorePharmaceutical distribution partner for Serrix consumer health products. Aswatson is shown as a key distribution partner distributing Serrix brands.
- StrathoscorePharmaceutical distribution partner for Serrix consumer health products. Strathos is shown as a key distribution partner distributing Serrix brands.
- SirowacorePharmaceutical distribution partner for Serrix consumer health products. Sirowa is shown as a key distribution partner distributing Serrix brands.
- NormoncorePharmaceutical distribution partner for Serrix consumer health products. Normon is shown as a key distribution partner distributing Serrix brands.
- Innovation Partners (Academic Institutions, Entrepreneurs, Start-Ups, Established Companies)coreSerrix actively seeks collaboration with innovation partners including academic institutions, entrepreneurs, start-ups, and established companies for joint ventures, co-development projects, strategic alliances in research, trademark licensing, and in-licensing or out-licensing of research or intellectual property. Focus areas include medicated skin care, paediatrics, mouth care, wound treatment, eyes, and ear/nose/throat.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
Serrix competitors and assessment
Company assessmentDirect peers
- Dr. Wolff Group: German private OTC/dermo-cosmetic company with proprietary brands (Alpecin, Linola, Alcina) of comparable size to Serrix; operates a multi-brand dermatology and consumer-health portfolio with international distributor reach — a tight size and category match.
- Almirall: Spanish specialty pharma with a clear dermatology focus, including OTC and prescription skin-care products; comparable given Serrix's dermatology-led brand portfolio (Mycosan antifungal, donttellmum eczema).
- Stada Arzneimittel: European-focused mid-size OTC and generics company distributing branded consumer health products across multiple European markets; comparable in geographic orientation and OTC/dermatology portfolio mix.
- Omega Pharma (Perrigo): Belgian-headquartered OTC specialist now under Perrigo, historically built by acquiring and growing niche OTC brands across Europe — the same brand-building, distributor-heavy playbook Serrix runs with Mycosan, SoreFix and donttellmum.
- Pierre Fabre Dermatologie: French dermo-cosmetic and OTC specialist with a broad dermatology portfolio (Avène, Ducray, A-Derma); comparable in OTC dermatology positioning and pharmacy-led European distribution model.
Broad incumbents
- Haleon: Global consumer-health major (ex-GSK) with leading OTC franchises in cold sores (Zovirax), antifungals (Lamisil) and oral health; one of the largest incumbents Serrix's brands compete against in European pharmacy channels.
- Perrigo Company: US-listed OTC private-label and store-brand leader that also owns the Omega Pharma European OTC portfolio; competes broadly with Serrix's categories but at vastly greater scale and channel power.
- Kenvue: J&J's former consumer-health spin-off (Neutrogena, Aveeno, Zyrtec) operating globally across OTC and skin care; relevant broad incumbent particularly against donttellmum's paediatric/eczema positioning.
- Bayer Consumer Health: Incumbent OTC giant with category-leading antifungals (Canesten) and a broad pharmacy footprint across Europe; competes with Mycosan in antifungals and with the broader Serrix portfolio in shelf access.
- Church & Dwight: US-listed consumer-health and household products company with an expanding OTC and personal-care portfolio; relevant comparator for OTC brand-building and category adjacencies.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Serrix social profiles
Digital presenceSerrix compliance and trust
Trust signalCompliance1 record
Serrix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Serrix leadership team
Management profileNumber of profiles
Profiles10 records
Serrix funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Serrix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Serrix
What does Serrix do?
Serrix develops and sells OTC (over-the-counter) consumer health products through three proprietary brands: Mycosan (antifungal foot care including fungal nail and athlete's foot treatments), SoreFix (cold sore treatment using a unique zinc formula), and donttellmum (paediatric skincare for babies and kids 0-12 years including eczema repair). Products are sold in over 25 countries worldwide through a distributor network serving consumers via pharmacies and drugstores.
Is Serrix a public or private company?
Serrix is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Serrix founded?
Serrix was founded in 2007. It employs 11 to 50 people.
Where is Serrix based?
Serrix is headquartered in Amsterdam, Netherlands, in the Europe region.
How does Serrix make money?
One revenue line is on record: consumer Health Product Sales.
Who are Serrix's main competitors?
Direct peers on record are Dr. Wolff Group, Almirall, Stada Arzneimittel, Omega Pharma (Perrigo) and Pierre Fabre Dermatologie. Broad incumbents are Haleon, Perrigo Company, Kenvue, Bayer Consumer Health and Church & Dwight.
Does Serrix have an API?
No public API is recorded for Serrix.
What industry is Serrix in?
Serrix's product category is OTC Consumer Health Products. Its primary akta.pro industry code is CRADAMAF, Dermatology OTC & Skin Health (Acne Treatments, Eczema/Psoriasis OTC, Antifungals, Wart Removal), with a secondary code of CRADAMAL, Foot Care & Orthotics OTC (Corn/Callus Care, Insoles, Athlete’s Foot Treatments). Its NAICS code is 42421 and its SIC code is 5122.